VACCENTIS AG – AGAINST CHRONIC AND MALIGNANT DISEASES
Vaccentis AG develops and produces patient-specific medicines. On the basis of complementary and natural medicine and the achievements of evidence-based medicine, we ensure that the proven medicines for autologous patient treatment are consistently perfected. We want to make our own contribution towards improving the chances of recovery in the area of chronic and malignant diseases.
VCC MEDICAL DEUTSCHLAND GMBH
VCC Medical Deutschland GmbH is established as the headquarter within the VCC Medical Group for Reniale® in Europe. The main activity is of course the supply of Reniale® to German patients. Furthermore, all competencies at VCC Medical Deutschland will be bundled in order to develop additional products according to the “Reniale® method” for other indications on a scientific and clinical level and to offer services in the fields of GMP Compliance and Regulatory Affairs to other pharmaceutical companies.
The company was initially founded at the headquarter of the sister company FBM-Pharma GmbH and moved to the new offices at the new business address in the Technology Centre Ludwigshafen on 1 January 2016. As a result, VCC Medical Deutschland GmbH is now equipped with both sufficient space for the further development of the company and a good infrastructure and an additional network, without losing the proximity to its sister company FBM-Pharma.
FBM-PHARMA „Gesellschaft für biologische Medizin mbH“, founded in 1995, focusses on manufacture of individual immunotherapeutic medicines based on patient’s material (blood/urine).
The complementary medical treatment approach is used in the causal therapy of autoimmune diseases of various types.
The individual immunotherapeutic medicines (individual immunotherapy from blood/plasma, AHIT® according to Dr. Kief, urexent®) meanwhile was administered to more than 17,000 patients and showed in many of them sustainable improvement in health status.
MISSION AND VISION
PIONEERING SPIRIT, INTEGRITY AND PERFECTION
We are pioneers and trailblazers in the fight against chronic and extremely serious illnesses. To this end, we develop ideas, products and treatments. So that we can channel all of our energy into achieving these objectives, our organizational structure is optimally adapted to the future technical challenges.
Trust, quality, integrity and perfection are paramount at Vaccentis. This applies just as much to our research and development as it does to our management. Short decision-making paths and a targeted use of all our resources have top priority. Our investors and business partners value our ability to operate in an economically sound manner and produce corresponding growth rates.
ENSURING OUR FUTURE SUCCESS
In the areas of both complementary and natural medicine and evidence-based medicine, innovative molecular diagnostics and therapy are opening up new opportunities for treatment. Many diseases that were difficult to treat in the past can now be alleviated and, in some cases, even cured.
INDEPENDENT TODAY AND IN THE FUTURE
The economic prospects in this sector are also more than promising. Against this backdrop, Vaccentis is establishing itself as an independent pharmaceutical company with its own basic research and development resources. The merger of Vaccentis AG, FBM-Pharma GmbH and VCC Medical Deutschland GmbH reduces the costs and risks of development and marketing. Ensuring that Vaccentis remains financially successful – including in the future.
BOARD OF DIRECTORS AND ADVISORY BOARD
Vaccentis has set itself the goal of achieving the highest standards in research, product manufacture and therapeutic treatment – combined with transparency and responsibility at all levels of the business. The Board of Directors and Advisory Council are strategically organized so as to achieve these objectives.
Chairman of the Board of Directors
Chief Executive Officer | Delegate of the Board of Directors
Chief Sales and Marketing Officer
Head of Quality Control, FBM-Pharma
Managing director of FBM-Pharma and VCC Medical
Head of Manufacturing, FBM-Pharma